Sarcoma trials in Romania

1 trial · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

• Phase 3Taking people
  A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  Where

  Brasov, Bucharest, Cluj-Napoca, Craiova, Suceava, Timisoara

  Age

  18 years and over

  People

  348 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06345729 · EU 2023-507776-42-00